Navigation Links
Synteract Releases SynCapture Version 1.5 of Its Hybrid Electronic Data Capture (EDC) System
Date:1/31/2012

SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- Synteract, Inc., a full-service contract research organization (CRO), has released upgrades to its electronic data capture system SynCapture™, providing customers with increased user functionality. SynCapture allows for clinical study data to be captured into a single database using multiple modes of entry including paper, fax, and web based, resulting in more seamless, flexible and cost effective data capture.

(Logo: http://photos.prnewswire.com/prnh/20111108/MM02925LOGO)

"We understand that low cost EDC is critical, especially in smaller trials," said Wendel Barr, chief executive officer at Synteract. "SynCapture has been an effective solution to handle the needs of our clients since it was first implemented in 2005.  SynCapture 1.5 integrates features that enhance our cost efficient EDC offering, so we can continue to meet each client's unique program requirements."

SynCapture 1.5 provides users the ability to re-query investigative sites on data collected, an upgrade sponsors requested. In addition, the new release brings enhanced audit trail legibility and functionality useful to all project team members, as well as features that increase the ease and efficiency of the query resolution process.

"SynCapture 1.5 provides users increased functionality and easier data collection," said Olivia Montano, senior director of clinical data management at Synteract. "The main reason for the upgrade was to improve the user experience.  We took into account direct requests from users, since customer service is so integral to what we do at Synteract. This SynCapture upgrade allows us to provide clients an improved option for on-time delivery of quality data to help them get to decision points faster."

About Synteract, Inc.

Synteract is a privately-held, full-service contract research organization, serving clinical trial needs of biotechnology, medical device, and pharmaceutical companies. Synteract provides high quality, customized service, working closely with drug and device sponsors. Headquartered in California, with offices in North Carolina and Czech Republic, Synteract offers clinical expertise in multiple therapeutic areas, including a strong emphasis in oncology, central nervous system (CNS), cardiovascular, respiratory, and ophthalmology. Information: http://www.synteract.com; (760) 268.8200.

CONTACT:

Rachel Hutman
Clearpoint Agency, for Synteract
rachel@clearpointagency.com
760-230-2424

 


'/>"/>
SOURCE Synteract, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. CEL-SCI Corporation Releases Letter to Shareholders
3. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
4. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
5. Immunosyn Corporation Releases SF-1019 Study Results
6. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
7. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
8. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
9. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
10. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
11. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017  Eli Lilly and Company (NYSE: ... $850 million in its U.S. operations in 2017. ... enterprise, including research laboratories, manufacturing sites, and general ... by demand for Lilly products, as well as ... targeting cancer, pain, diabetes and other unmet medical ...
(Date:3/24/2017)... GENEVA , March 24, 2017 /PRNewswire/ ... Day revitalizes efforts to develop sutezolid as effective response ... Tuberculosis Day, TB Alliance and the Medicines Patent Pool ... of sutezolid, an antibiotic drug candidate which demonstrated encouraging ... development of sutezolid in combination with other TB drugs ...
(Date:3/23/2017)... The key factors driving the growth of dialysis ... growth and increasing healthcare expenditure. Some of the noteworthy trends ... ESRD patients, rising demand for home PD treatment and huge ... market is hindered by high treatment costs and stringent regulations. ... Complete ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... the year of enhancements, upgrading their training and leads programs. , In February, ... Reserved for elite sales agents, Performance Partners is designed to teach how to ...
(Date:3/24/2017)... ... ... “End Time GPS”: a dauntless and enlightened study of the second-coming ... the creation of published author, Wesley Gerboth, a World War II veteran, with a ... Now, at age ninety-one, he shares the Wisdom God bestowed upon him in this ...
(Date:3/24/2017)... ... ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous ... the fullest, as God intended. “The Adventures of Joey, The Dog Who Barks at ... her passion for writing, especially about truth and human behavior. , Published by Christian ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF ... the greater Houston Area. The new location is located at 2255 E. Mossy Oaks ... Springwoods Village. This newest location will provide patients living in the north Houston area ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... City Convention Center at 10 North Broadway Avenue, will be an educational and ... relevant, practical instruction in the management of chronic pain. , Oklahoma is in ...
Breaking Medicine News(10 mins):